RT Journal Article
T1 Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma.
A1 Gómez-Bastero Fernández, Ana
A1 Medina Gallardo, Juan Francisco
A1 Delgado Romero, Julio
A1 Romero Falcón, Auxiliadora
A1 Benito Bernáldez, Cristina
A1 Gallego Borrego, Javier
A1 Álvarez-Gutiérrez, Francisco Javier
K1 daily clinical practice
K1 monoclonal antibodies
K1 severe uncontrolled asthma
K1 treatment optimization
AB Benralizumab is a monoclonal antibody that targets the α subunit of the IL-5 receptor. Clinical trials have demonstrated the efficacy of this agent with respect to lung function and symptom control in patients with refractory eosinophilic asthma. However, few studies have evaluated the efficacy of benralizumab after switching previous treatment with other monoclonal antibodies. We performed a multicenter retrospective study under conditions of daily clinical practice. The study population comprised consecutively included patients with severe refractory eosinophilic asthma whose initial treatment with omalizumab or mepolizumab was switched to benralizumab. Patients were evaluated at 4 and 12 months after starting treatment with benralizumab. We analyzed asthma control, number of severe exacerbations, corticosteroid cycles, visits to the emergency department, and hospital admissions, as well as lung function. Similarly, we evaluated the response to treatment according to previously established criteria. We evaluated 40 patients who switched from omalizumab (n=16) or mepolizumab (n=24) to benralizumab. The reasons for switching were lack of response in 30 cases, adverse effects in 9, and patient request in 1. Switching was followed by a significant decrease in the number of exacerbations, visits to the emergency department, and corticosteroid cycles, as well as improved ACT both at 4 and 12 months. However, no significant improvement in lung function was observed. Asthma control (including complete response and control) was achieved in 55% of patients (n=22) at 12 months. Specifically, a complete response was achieved in 30% of patients at 12 months (66.7% switching from omalizumab and 33.3% from mepolizumab). Patients diagnosed with severe refractory eosinophilic asthma who experience a partial response with omalizumab or mepolizumab could benefit from switching to benralizumab. This approach can reduce the number of exacerbations, visits to the emergency department, and corticosteroid cycles and improve control of asthma.
SN 1178-6965
YR 2022
FD 2022-05-25
LK http://hdl.handle.net/10668/20469
UL http://hdl.handle.net/10668/20469
LA en
DS RISalud
RD Apr 7, 2025